NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, News, & Analysis

$48.05
-1.52 (-3.07 %)
(As of 06/16/2019 01:38 PM ET)
Today's Range
$47.91
Now: $48.05
$49.84
50-Day Range
$46.17
MA: $50.30
$57.16
52-Week Range
$41.63
Now: $48.05
$99.82
Volume454,660 shs
Average Volume427,862 shs
Market Capitalization$2.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.33
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$94.39 million
Book Value$11.82 per share

Profitability

Net Income$-346,020,000.00
Net Margins-300.63%

Miscellaneous

Employees482
Market Cap$2.82 billion
Next Earnings Date8/1/2019 (Estimated)
OptionableOptionable

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings results on Thursday, May, 2nd. The biopharmaceutical company reported ($1.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.74) by $0.15. The biopharmaceutical company earned $30.20 million during the quarter, compared to analyst estimates of $22.69 million. Agios Pharmaceuticals had a negative net margin of 300.63% and a negative return on equity of 48.19%. The business's revenue was up 243.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.63) earnings per share. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 1st 2019. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

10 analysts have issued 12 month price targets for Agios Pharmaceuticals' stock. Their forecasts range from $55.00 to $123.00. On average, they anticipate Agios Pharmaceuticals' share price to reach $86.1429 in the next year. This suggests a possible upside of 79.3% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Agios' first wholly owned precision medicine, Tibsovo, was approved by the FDA last July 2018 for treating R/R AML. The drug generated strong sales in the reported quarter. Tibsovo’s label expansion studies also look promising with the FDA recently granting a priority review in first-line setting. Agios’ progress with pipeline candidates, namely AG-348 and AG-881, has been quite impressive too. We are also optimistic about Agios' collaboration with Celgene as it provides the company with regular funds and royalties from Idhifa sales. However, Agios’ heavy dependence on partner Celgene for royalties remains an overhang. Stiff competition from big pharma companies is another matter of concern for the company. Shares have outperformed the industry in the year so far. Loss estimates have widened ahead of Q1 earnings. Agios has a positive record of earnings surprises in the recent quarters." (4/25/2019)
  • 2. Canaccord Genuity analysts commented, "We maintain a favorable view on Fouse as the CEO given her expensive experience at Laboratories, holding various senior roles focusing on corporate strategies, finance, and operations. We believe Fouse will help maintain AGIO’s heading in launching the approved products and developing the pipeline." (9/5/2018)
  • 3. Needham & Company LLC analysts commented, "BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn)." (8/2/2018)

Has Agios Pharmaceuticals been receiving favorable news coverage?

News stories about AGIO stock have been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Agios Pharmaceuticals.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), bluebird bio (BLUE), Tesla (TSLA), Allergan (AGN) and Biogen (BIIB).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Jacqualyn A. Fouse, Chief Executive Officer & Director
  • Andrew J. Hirsch, CFO & Head-Corporate Development
  • Scott Biller, Chief Scientific Officer
  • Chris Bowden, Chief Medical Officer
  • Clive Patience, Senior Vice President-Technical Operations

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (14.92%), Wellington Management Group LLP (13.88%), BlackRock Inc. (5.68%), First Trust Advisors LP (3.02%), Goldman Sachs Group Inc. (2.79%) and Clearbridge Investments LLC (2.58%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, John Maraganore, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which institutional investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Spark Investment Management LLC, Wells Fargo & Company MN, Morgan Stanley, Cutler Group LP, Geode Capital Management LLC, Handelsbanken Fonder AB and Man Group plc. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, John Maraganore, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which institutional investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Westfield Capital Management Co. LP, Goldman Sachs Group Inc., Jennison Associates LLC, Amundi Pioneer Asset Management Inc., Artisan Partners Limited Partnership, Sector Gamma AS and ArrowMark Colorado Holdings LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $48.05.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $2.82 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.View Additional Information About Agios Pharmaceuticals.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com/.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  361 (Vote Outperform)
Underperform Votes:  318 (Vote Underperform)
Total Votes:  679
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel